Patients with chronic HBV may benefit from RO7049389

2021-07-21

Patients with chronic hepatitis B who were treated with the core protein allosteric modulator RO7049389 had decreases in HBV DNA and HBV RNA, according to a study led by Man-Fung Yuen, MD, PhD, of the University of Hong Kong, and published in The Lancet Gastroenterology and Hepatology. Commonly reported side effects included headaches, diarrhea, increased liver enzymes and upper respiratory infections.

Full story:

ACG SmartBrief

Providing the latest, need-to-know medical headlines and news that affect gastroenterologists

Designed specifically for digestive disorder specialists, ACG SmartBrief is a FREE, twice-weekly e-mail newsletter. By providing the latest, need-to-know medical headlines and news that affect gastroenterologists, ACG SmartBrief saves you time and keeps you smart.